ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...

Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...

But sales of products such as Nurtec and the vaccine Abrysvo that the company has been counting on are rising, and an ...

vaccine to its list of prequalified vaccines. Abrysvo, which is now the first maternal RSV vaccine to be prequalified by the organisation, aims to prevent RSV-associated lower respiratory tract ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

The European Commission (EC) has expanded the approval of Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, to include adults aged 18 to 59 years at increased risk of lower ...

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its RSV vaccine, Abrysvo. The vaccine has been approved for the prevention of ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC ...